Pelthos Therapeutics (PTHS) Stock Forecast & Price Target

Compare

70 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTHS Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Pelthos

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTHS Stock 12 Month Forecast

Average Price Target

$58.00

▲(143.19% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Pelthos Therapeutics in the last 3 months. The average price target is $58.00 with a high forecast of $75.00 and a low forecast of $48.00. The average price target represents a 143.19% change from the last price of $23.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","76":"$76","22.75":"$22.8","40.5":"$40.5","58.25":"$58.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$58.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$48.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,22.75,40.5,58.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,28.07076923076923,31.981538461538463,35.892307692307696,39.80307692307692,43.713846153846156,47.62461538461538,51.535384615384615,55.44615384615385,59.35692307692308,63.267692307692315,67.17846153846155,71.08923076923077,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,26.763076923076923,29.366153846153846,31.96923076923077,34.572307692307696,37.175384615384615,39.77846153846154,42.38153846153847,44.98461538461539,47.58769230769231,50.190769230769234,52.79384615384616,55.39692307692309,{"y":58,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.16,25.993846153846153,27.82769230769231,29.661538461538463,31.495384615384616,33.32923076923077,35.16307692307692,36.99692307692308,38.830769230769235,40.66461538461539,42.49846153846154,44.332307692307694,46.16615384615385,{"y":48,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.37,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.37,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.37,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.37,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6.37,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.46,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.46,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.3,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.16,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$75.00

Average Price Target$58.00

Lowest Price Target$48.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

James Molloy

Alliance Global Partners

$75

Buy

214.47%

Upside

Reiterated

03/16/26

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)Reiterate Buy rang and $75 price target. Our price target is based on a sum-of-the-parts analysis.

Brandon Folkes

H.C. Wainwright

$60

Buy

151.57%

Upside

Reiterated

03/06/26

Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), Pelthos Therapeutics (PTHS)

David Amsellem

Piper Sandler

$48

Buy

101.26%

Upside

Initiated

02/27/26

Pelthos Therapeutics initiated with an Overweight at Piper SandlerPelthos Therapeutics initiated with an Overweight at Piper Sandler

Jonathan Aschoff

Roth MKM

$57→$55

Buy

130.61%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Pelthos Therapeutics (NYSE MKT: PTHS)

Jeff Jones

Oppenheimer

$57→$60

Buy

151.57%

Upside

Reiterated

01/26/26

Pelthos Therapeutics price target raised to $60 from $57 at OppenheimerPelthos Therapeutics price target raised to $60 from $57 at Oppenheimer

Thomas Flaten

Lake Street

$50

Buy

109.64%

Upside

Reiterated

01/06/26

Analysts Offer Insights on Healthcare Companies: OptimizeRx (NASDAQ: OPRX) and Pelthos Therapeutics (NYSE MKT: PTHS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

James Molloy

Alliance Global Partners

$75

Buy

214.47%

Upside

Reiterated

03/16/26

Brandon Folkes

H.C. Wainwright

$60

Buy

151.57%

Upside

Reiterated

03/06/26

Analysts Are Bullish on These Healthcare Stocks: Cooper Co (COO), Pelthos Therapeutics (PTHS)

David Amsellem

Piper Sandler

$48

Buy

101.26%

Upside

Initiated

02/27/26

Pelthos Therapeutics initiated with an Overweight at Piper SandlerPelthos Therapeutics initiated with an Overweight at Piper Sandler

Jonathan Aschoff

Roth MKM

$57→$55

Buy

130.61%

Upside

Reiterated

02/26/26

Analysts Offer Insights on Healthcare Companies: RxSight (NASDAQ: RXST) and Pelthos Therapeutics (NYSE MKT: PTHS)

Jeff Jones

Oppenheimer

$57→$60

Buy

151.57%

Upside

Reiterated

01/26/26

Pelthos Therapeutics price target raised to $60 from $57 at OppenheimerPelthos Therapeutics price target raised to $60 from $57 at Oppenheimer

Thomas Flaten

Lake Street

$50

Buy

109.64%

Upside

Reiterated

01/06/26

Analysts Offer Insights on Healthcare Companies: OptimizeRx (NASDAQ: OPRX) and Pelthos Therapeutics (NYSE MKT: PTHS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pelthos Therapeutics

3 Months

xxx

Success Rate

2/7 ratings generated profit

Average Return

-3.81%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 28.57% of your transactions generating a profit, with an average return of -3.81% per trade.

1 Year

James MolloyAlliance Global Partners

Success Rate

2/7 ratings generated profit

Average Return

-5.36%

reiterated a buy rating 3 days ago

Copying James Molloy's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -5.36% per trade.

2 Years

xxx

Success Rate

3/7 ratings generated profit

Average Return

+7.20%

reiterated a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of +7.20% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTHS Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTHS has received 18 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. PTHS average Analyst price target in the past 3 months is 58.00.

Each month's total comprises the sum of three months' worth of ratings.

PTHS Financial Forecast

PTHS Earnings Forecast

Next quarter’s earnings estimate for PTHS is -$3.70 with a range of -$5.15 to -$1.55. The previous quarter’s EPS was -$5.30. PTHS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year PTHS has its overall industry.

PTHS Sales Forecast

Next quarter’s sales forecast for PTHS is $9.09M with a range of $8.81M to $9.40M. The previous quarter’s sales results were $7.41M. PTHS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year PTHS has its overall industry.

PTHS Stock Forecast FAQ

What is PTHS’s average 12-month price target, according to analysts?

Based on analyst ratings, Pelthos Therapeutics’s 12-month average price target is 58.00.

What is PTHS’s upside potential, based on the analysts’ average price target?

Pelthos Therapeutics has 143.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTHS a Buy, Sell or Hold?

Pelthos Therapeutics has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Pelthos Therapeutics’s price target?

The average price target for Pelthos Therapeutics is 58.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $48.00. The average price target represents 143.19% Increase from the current price of $23.85.

What do analysts say about Pelthos Therapeutics?

Pelthos Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of PTHS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Pelthos Therapeutics (PTHS) Stock Forecast & Price Target

PTHS Analyst Ratings

PTHS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Pelthos Therapeutics

PTHS Analyst Recommendation Trends

PTHS Financial Forecast

PTHS Earnings Forecast

PTHS Sales Forecast

PTHS Stock Forecast FAQ

Detailed List of Analyst Forecasts